Next Generation
Immune Checkpoint Inhibitors and Stimulators Market by Roots Analysis





Therapies targeting novel inhibitory and stimulatory immune
checkpoints have been shown to possess substantial therapeutic potential, both
as monotherapies and in combination with other interventions, across multiple
disease interventions





Roots Analysis is pleased to
announce the publication of its recent study, titled, “Next Generation Immune Checkpoint
Inhibitors and Stimulators Market, 2020-2030.”





The
report features an extensive study of the current market landscape, offering an
informed opinion on the likely adoption of these therapies over the next
decade. It features an in-depth analysis, highlighting the capabilities of
various stakeholders engaged in this domain. In addition to other elements, the
study includes:


§ A
detailed assessment of the current market landscape of drug developers engaged
in the development of next generation immune checkpoint modulators.


§ A
detailed analysis of more than 590 completed, ongoing and planned clinical
studies of next generation immune checkpoint inhibitors and stimulators.


§ Detailed
profiles of developers of next generation immune checkpoint modulators (shortlisted
on the basis of the number of pipeline products).


§ An
in-depth analysis of more than 490 grants that have been awarded to research
institutes engaged in next generation immune checkpoint therapy-related
projects.


§ An
analysis of the partnerships that have been established in this domain, in the
recent past.


§ A competitiveness
analysis of biological targets, featuring insightful pictorial summaries and
representations.


§ An
analysis of the initiatives of big biopharma players engaged in this domain.


§
A detailed market forecast, featuring analysis of the
current and projected future opportunity across key market segments (listed
below)


Target
Disease Indication



§ Breast
Cancer


§ Chronic
Lymphocytic Leukemia


§ Colorectal
Cancer


§ Head
and Neck Cancer


§ Lung
Cancer


§ Lupus
Nephritis


§ Melanoma


§ Multiple
Myeloma


§ Primary
Sjögren's Syndrome


§ Others


Target
Immune Checkpoint



§ B7-H3


§ CD38


§ CD40


§ CD47


§ Others


Mechanism of
Action



§ Inhibitory


§ Stimulatory


Therapeutic
Modality



§ Monoclonal
Antibody


§ Small
Molecule


Type of
Therapy



§ Monotherapy


§ Combination
Therapy


Route of
Administration



§ Intravenous


§ Subcutaneous


§ Others


Key
Geographical Region



§ North
America


§ Europe


§ Asia-Pacific
and the Rest of the World





To
Request for sample report - https://www.rootsanalysis.com/reports/303/request-sample.html





Key
companies covered in the report


§ Bristol Myers Squibb


§ GlaxoSmithKline


§ Incyte


§ Novartis


§ Trillium Therapeutics





For
more information please click on the following link:


https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html





Other Recent Offerings


1.
Neoantigen
Targeted Therapies Market, 2019-2030


2.
Bispecific
Antibody Therapeutics Market (4th Edition), 2019-2030


3.
Global
Stem Cells Market: Focus on Clinical Therapies, 2020-2030





About Roots Analysis


Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com





Contact Information


Roots
Analysis Private Limited


Gaurav Chaudhary


+1 (415) 800 3415


ben.johnson@rootsanalysis.com


Facebook - https://www.facebook.com/RootsAnalysis


LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/


Twitter - https://twitter.com/RootsAnalysis